| Monash IVF Group Limited (MVF) ORDINARY FULLY PAID |
Health Care |
$294 |
MVF FY25 Appendix 4E and Financial Report
|
22 Aug 2025 9:36AM |
$0.805 |
$0.755 |
fallen by
6.21%
|
|
MVF - Price-sensitive ASX Announcement
Full Release
Key Points
- Monash IVF Group Limited released its FY25 Appendix 4E and Financial Report with detailed financial statements and operational commentary.
- The report outlines statutory and underlying financial results, noting revenue growth, profit performance, and dividend declarations.
- Key business segments covered include IVF, diagnostics, and international operations with analysis of market trends and performance drivers.
- The company highlights strategic initiatives centered on digital transformation, patient care enhancement, and clinical excellence.
- Sustainability, investment in technology, and expansion in domestic and international markets are emphasized.
- Risk management practices, governance, and executive remuneration are disclosed in compliance with regulatory requirements.
- The report includes director and auditor declarations regarding the integrity and fairness of the financial statements.
- Monash IVF Group remains focused on growth through innovation, workforce development, and responding to evolving market demands.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| QX Resources Limited (QXR) ORDINARY FULLY PAID |
Materials |
$8 |
Trading Halt
|
22 Aug 2025 9:36AM |
$0.004 |
$0.004 |
fallen by
0%
|
|
QXR - Price-sensitive ASX Announcement
Full Release
Key Points
- QX Resources Limited (QXR) requested a trading halt to be applied by the Australian Securities Exchange (ASX).
- The trading halt was requested pending an announcement regarding a capital raising.
- The trading halt is necessary to ensure the market is fully informed and to prevent trading on an uninformed basis.
- The company requested that the trading halt remains in place until the earlier of commencement of trading on 27 May 2024 or the release of the relevant announcement.
- The request for trading halt was made by the Managing Director, Stephen Promnitz.
- No further details on the capital raising or its terms are disclosed in the halt request letter.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Somerset Minerals Limited (SMM) ORDINARY FULLY PAID |
Materials |
$17 |
Cleansing Notice
|
22 Aug 2025 9:36AM |
$0.015 |
$0.014 |
fallen by
6.67%
|
|
| DigitalX Limited (DCC) ORDINARY FULLY PAID |
Information Technology |
$60 |
Treasury Information - July 2025
|
22 Aug 2025 9:35AM |
$0.069 |
$0.040 |
fallen by
42.03%
|
|
DCC - Price-sensitive ASX Announcement
Full Release
Key Points
- Overview of DigitalX Treasury structure and operations
- Details on digital asset management strategies
- Governance and compliance protocols
- Recent treasury performance and updates
- Risk management procedures and digital asset custody
- Commitment to transparency and robust controls
- Alignment with regulatory standards
- Future initiatives for treasury security and efficiency
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Somerset Minerals Limited (SMM) ORDINARY FULLY PAID |
Materials |
$17 |
Application for quotation of securities - SMM
|
22 Aug 2025 9:34AM |
$0.015 |
$0.014 |
fallen by
6.67%
|
|
| Rural Funds Group (RFF) FULLY PAID UNITS STAPLED SECURITIES |
Real Estate |
$774 |
Presentation - FY25 financial results
|
22 Aug 2025 9:34AM |
$1.950 |
$1.985 |
risen by
1.79%
|
|
| Articore Group Limited (ATG) ORDINARY FULLY PAID |
Consumer Discretionary |
$73 |
Extraordinary General Meeting Chair address and presentation
|
22 Aug 2025 9:34AM |
$0.255 |
$0.250 |
fallen by
1.96%
|
|
| Nyrada Inc (NYR) CHESS DEPOSITARY INTERESTS 1:1 US PROHIBITED |
Health Care |
$284 |
Securities Trading Policy
|
22 Aug 2025 9:33AM |
$0.270 |
$1.185 |
risen by
338.89%
|
|
| Rural Funds Group (RFF) FULLY PAID UNITS STAPLED SECURITIES |
Real Estate |
$774 |
FY25 financial results summary
|
22 Aug 2025 9:31AM |
$1.950 |
$1.985 |
risen by
1.79%
|
|
| Centuria Industrial REIT (CIP) ORDINARY UNITS FULLY PAID |
Real Estate |
$2,082 |
Update - Notification of buy-back - CIP
|
22 Aug 2025 9:30AM |
$3.390 |
$3.335 |
fallen by
1.62%
|
|
| Rural Funds Group (RFF) FULLY PAID UNITS STAPLED SECURITIES |
Real Estate |
$774 |
Full Year Statutory Accounts
|
22 Aug 2025 9:30AM |
$1.950 |
$1.985 |
risen by
1.79%
|
|
| Clinuvel Pharmaceuticals Limited (CUV) ORDINARY FULLY PAID |
Health Care |
$635 |
CLINUVEL preparing upgrade of ADR program, NASDAQ uplist
|
22 Aug 2025 9:30AM |
$11.990 |
$12.640 |
risen by
5.42%
|
|
CUV - Price-sensitive ASX Announcement
Full Release
Key Points
- Clinuvel Pharmaceuticals Limited announces plans to upgrade its ADR program to NASDAQ.
- The upgrade aims to increase visibility in US capital markets and attract a broader investor base.
- Clinuvel is currently listed on the ASX and the OTC market under NASDAQ’s CLVLY ticker.
- The company is a pioneer in photomedicine and treats patients with unmet medical needs.
- The uplisting process includes meeting regulatory and compliance requirements for NASDAQ.
- Clinuvel expects the move will improve ADR trading liquidity and benefit shareholders.
- Core business focus and operations will remain unchanged during and after the transition.
- The company will continue to comply with current OTC ADR requirements until NASDAQ listing is achieved.
- Shareholders are to be kept informed about progress and significant developments regarding the uplisting.
- The announcement is part of Clinuvel’s strategy to strengthen its US presence and capital market profile.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Spenda Limited (SPX) ORDINARY FULLY PAID |
Information Technology |
$14 |
Notification regarding unquoted securities - SPX
|
22 Aug 2025 9:28AM |
$0.006 |
$0.003 |
fallen by
58.33%
|
|
| Rural Funds Group (RFF) FULLY PAID UNITS STAPLED SECURITIES |
Real Estate |
$774 |
Appendix 4E
|
22 Aug 2025 9:28AM |
$1.950 |
$1.985 |
risen by
1.79%
|
|
| WAM Income Maximiser Limited (WMX) ORDINARY FULLY PAID |
Financials |
$309 |
Appendix 4G
|
22 Aug 2025 9:27AM |
$1.640 |
$1.603 |
fallen by
2.29%
|
|
| GDI Property Group (GDI) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Real Estate |
$340 |
Becoming a substantial holder
|
22 Aug 2025 9:27AM |
$0.670 |
$0.630 |
fallen by
5.97%
|
|
| Dart Mining NL (DTM) ORDINARY FULLY PAID |
Materials |
$8 |
Security Class Suspension from Quotation - DTMOC
|
22 Aug 2025 9:27AM |
$0.002 |
$0.038 |
risen by
1,800%
|
|
DTM - Price-sensitive ASX Announcement
Full Release
Key Points
- Dart Mining NL requested a voluntary suspension of its DTMOC securities from quotation.
- The suspension began on 13 June 2024 at the start of trading.
- The suspension is related to a pending announcement about a proposed capital raising.
- ASX Listing Rule 17.2 is cited as the basis for the suspension procedure.
- Trading in DTMOC securities will remain suspended until the announcement is released or ASX decides otherwise.
- The company anticipates making the announcement and seeking reinstatement by 17 June 2024.
- Other securities issued by Dart Mining NL are not affected by this suspension.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Integral Diagnostics Limited (IDX) ORDINARY FULLY PAID |
Health Care |
$936 |
Release of Ordinary Shares from Escrow
|
22 Aug 2025 9:26AM |
$2.650 |
$2.510 |
fallen by
5.28%
|
|
| Accent Group Limited (AX1) ORDINARY FULLY PAID |
Consumer Discretionary |
$565 |
Appendix 4G and FY25 Corporate Governance Statement
|
22 Aug 2025 9:25AM |
$1.660 |
$0.940 |
fallen by
43.37%
|
|
| Spenda Limited (SPX) ORDINARY FULLY PAID |
Information Technology |
$14 |
Notification regarding unquoted securities - SPX
|
22 Aug 2025 9:24AM |
$0.006 |
$0.003 |
fallen by
58.33%
|
|
| Viridis Mining and Minerals Limited (VMM) ORDINARY FULLY PAID |
Materials |
$139 |
Proposed issue of securities - VMM
|
22 Aug 2025 9:24AM |
$1.195 |
$1.250 |
risen by
4.60%
|
|
| Viridis Mining and Minerals Limited (VMM) ORDINARY FULLY PAID |
Materials |
$139 |
VMM Bolsters Strategic Position & Enhances Project Scale
|
22 Aug 2025 9:24AM |
$1.195 |
$1.250 |
risen by
4.60%
|
|
VMM - Price-sensitive ASX Announcement
Full Release
Key Points
- VMM has acquired rights to additional tenements at the Colossus Project in Brazil.
- The expansion significantly increases the project's scale and potential for ionic adsorption clay (IAC) rare earths.
- The acquisition supports VMM’s strategy to become a leading global supplier of rare earth elements.
- The announcement details the terms of acquisition and strategic rationale for the expansion.
- Colossus Project is located in a highly prospective rare earth region, considered vital for future supply chains.
- VMM emphasizes innovation in exploration and adherence to ESG and operational excellence.
- The move is expected to positively impact resource potential and shareholder value.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Diversified United Investment Limited (DUI) ORDINARY FULLY PAID |
Financials |
$1,162 |
Dividend/Distribution - DUI
|
22 Aug 2025 9:23AM |
$5.470 |
$5.420 |
fallen by
0.91%
|
|
| Diversified United Investment Limited (DUI) ORDINARY FULLY PAID |
Financials |
$1,162 |
Appendix 4E - 30 June 2025 Financial Report
|
22 Aug 2025 9:23AM |
$5.470 |
$5.420 |
fallen by
0.91%
|
|
DUI - Price-sensitive ASX Announcement
Full Release
Key Points
- Appendix 4E and Financial Report for year ending 30 June 2025.
- Diversified United Investment Limited's principal activity is investment in equities.
- Comprehensive financial statements including income, balance sheet, and cash flow.
- Discussion of portfolio performance and market influences.
- Dividends declared and paid for the year are disclosed.
- Summary of accounting policies and compliance with AASB standards.
- Details of directors, executive remuneration, and related party transactions.
- Major changes in fair value of investments are reported.
- Auditor’s independence declaration and audit opinion included.
- Risk management and corporate governance disclosures provided.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| LTR Pharma Ltd (LTP) ORDINARY FULLY PAID |
Health Care |
$130 |
18-Month Shelf Life Strengthens SPONTAN Commercialisation
|
22 Aug 2025 9:23AM |
$0.360 |
$0.715 |
risen by
98.61%
|
|
LTP - Price-sensitive ASX Announcement
Full Release
Key Points
- LTR Pharma Ltd has announced that the Therapeutic Goods Administration (TGA) has approved an 18-month shelf life for its product SPONTAN.
- The extension of shelf life is based on robust stability data submitted to the TGA as part of the ARTG registration process.
- SPONTAN is an orodispersible film (ODF) formulation of sildenafil, intended to treat erectile dysfunction (ED).
- The increased shelf life will provide greater confidence for pharmacists, prescribers, wholesalers, and patients in the commercialisation of SPONTAN.
- Preparations are underway for the commercial launch of SPONTAN in Q2 2024, with discussions ongoing with wholesalers and pharmacy groups.
- LTR Pharma believes that the extended shelf life will allow for optimal wholesaler and pharmacy uptake and stock management.
- The announcement is in line with the company’s strategy to ensure strong commercial launch conditions for SPONTAN.
- LTR Pharma is continuing to prepare for an Australia-wide launch, with the product now validated for 18 months shelf life at room temperature.
- The company reiterates its commitment to bringing innovative, patient-friendly ED treatments to market.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.